News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
104last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Simply Wall St.2d agobullish
Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises QuestionsStockStory89d agobullish
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded GuidanceSimply Wall St.92d agobullish
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting BuybacksSimply Wall St.92d agobullish
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?Investor's Business Daily93d agobullish
Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish VolumeMT Newswires180d agobullish
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan StanleySimply Wall St.190d agobullish
How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution RiskInsider Monkey203d agobullish
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?